The pharmacological management of acute behavioural disturbance: Data from a clinical audit conducted in UK mental health services.


Journal

Journal of psychopharmacology (Oxford, England)
ISSN: 1461-7285
Titre abrégé: J Psychopharmacol
Pays: United States
ID NLM: 8907828

Informations de publication

Date de publication:
04 2019
Historique:
pubmed: 20 12 2018
medline: 2 6 2020
entrez: 20 12 2018
Statut: ppublish

Résumé

A quality improvement programme addressing prescribing practice for acutely disturbed behaviour was initiated by the Prescribing Observatory for Mental Health. This study analysed data from a baseline clinical audit conducted in inpatient mental health services in member trusts. Fifty-eight mental health services submitted data on 2172 episodes of acutely disturbed behaviour. A benzodiazepine alone was administered in 60% of the 1091 episodes where oral medication only was used and in 39% of the 1081 episodes where parenteral medication (rapid tranquillisation) was used. Haloperidol was combined with lorazepam in 22% of rapid tranquillisation episodes and with promethazine in 3%. Physical violence towards others was strongly associated with receiving rapid tranquillisation in men (odds ratio 1.74, 1.25-2.44; p<0.001) as was actual or attempted self-harm in women (odds ratio 1.87, 1.19-2.94; p=0.007). Where physical violence towards others was exhibited, a benzodiazepine and antipsychotic was more likely to be prescribed than a benzodiazepine alone (odds ratio 1.39, 1.00-1.92; p=0.05). The data suggested that 25% of patients were at least 'extremely or continuously active' in the hour after rapid tranquillisation was administered. The current management of acutely disturbed behaviour with parenteral medication may fail to achieve a calming effect in up to a quarter of episodes. The most common rapid tranquillisation combination used was lorazepam and haloperidol, for which the randomised controlled trial evidence is very limited. Rapid tranquillisation prescribing practice was not wholly consistent with the relevant National Institute for Health and Care Excellence guideline, which recommends intramuscular lorazepam on its own or intramuscular haloperidol combined with intramuscular promethazine. Clinical factors prompting the use of rapid tranquillisation rather than oral medication may differ between the genders.

Sections du résumé

BACKGROUND
A quality improvement programme addressing prescribing practice for acutely disturbed behaviour was initiated by the Prescribing Observatory for Mental Health.
METHOD
This study analysed data from a baseline clinical audit conducted in inpatient mental health services in member trusts.
RESULTS
Fifty-eight mental health services submitted data on 2172 episodes of acutely disturbed behaviour. A benzodiazepine alone was administered in 60% of the 1091 episodes where oral medication only was used and in 39% of the 1081 episodes where parenteral medication (rapid tranquillisation) was used. Haloperidol was combined with lorazepam in 22% of rapid tranquillisation episodes and with promethazine in 3%. Physical violence towards others was strongly associated with receiving rapid tranquillisation in men (odds ratio 1.74, 1.25-2.44; p<0.001) as was actual or attempted self-harm in women (odds ratio 1.87, 1.19-2.94; p=0.007). Where physical violence towards others was exhibited, a benzodiazepine and antipsychotic was more likely to be prescribed than a benzodiazepine alone (odds ratio 1.39, 1.00-1.92; p=0.05). The data suggested that 25% of patients were at least 'extremely or continuously active' in the hour after rapid tranquillisation was administered.
CONCLUSION
The current management of acutely disturbed behaviour with parenteral medication may fail to achieve a calming effect in up to a quarter of episodes. The most common rapid tranquillisation combination used was lorazepam and haloperidol, for which the randomised controlled trial evidence is very limited. Rapid tranquillisation prescribing practice was not wholly consistent with the relevant National Institute for Health and Care Excellence guideline, which recommends intramuscular lorazepam on its own or intramuscular haloperidol combined with intramuscular promethazine. Clinical factors prompting the use of rapid tranquillisation rather than oral medication may differ between the genders.

Identifiants

pubmed: 30565486
doi: 10.1177/0269881118817170
pmc: PMC6431784
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

472-481

Références

BMC Psychiatry. 2013 Sep 18;13:225
pubmed: 24044673
Int J Clin Pract. 2008 Aug;62(8):1237-45
pubmed: 18564202
PLoS Med. 2009 Aug;6(8):e1000120
pubmed: 19668362
BMJ. 2003 Sep 27;327(7417):708-13
pubmed: 14512476
J Psychiatr Res. 2002 Mar-Apr;36(2):87-95
pubmed: 11777497
Drug Saf. 2002;25(2):91-110
pubmed: 11888352
Cochrane Database Syst Rev. 2015 Dec 21;(12):CD003441
pubmed: 26689942
Am J Psychiatry. 1992 Apr;149(4):506-10
pubmed: 1348161
J Clin Psychiatry. 2007 Dec;68(12):1876-85
pubmed: 18162018
Neuropsychiatr Dis Treat. 2017 Jan 16;13:161-175
pubmed: 28144147
Br J Psychiatry. 2004 Jul;185:63-9
pubmed: 15231557
N Engl J Med. 2006 Nov 16;355(20):2064-6
pubmed: 17108340
Am J Emerg Med. 1997 Jul;15(4):335-40
pubmed: 9217519
Aust N Z J Psychiatry. 2002 Oct;36(5):649-56
pubmed: 12225449
J Clin Psychiatry. 2011 Jan;72(1):e01
pubmed: 21272508
J Clin Psychiatry. 2000;61 Suppl 8:43-9; discussion 50-1
pubmed: 10811243
J Psychiatr Res. 2015 Sep;68:198-209
pubmed: 26228420
BMJ. 2007 Oct 27;335(7625):865
pubmed: 17954514
Cochrane Database Syst Rev. 2012 Nov 14;11:CD009377
pubmed: 23152276
Lancet. 2000 Mar 25;355(9209):1048-52
pubmed: 10744090
West J Emerg Med. 2012 Feb;13(1):1-2
pubmed: 22461914
BMJ. 2007 Oct 27;335(7625):869
pubmed: 17954515
J Clin Psychiatry. 2004 Mar;65(3):386-94
pubmed: 15096079
Braz J Psychiatry. 2011 Mar;33(1):30-9
pubmed: 21537720
World J Biol Psychiatry. 2016;17(2):86-128
pubmed: 26912127
BMJ. 2000 Dec 2;321(7273):1371-6
pubmed: 11099280
Br J Psychiatry. 1992 Jun;160:831-5
pubmed: 1352166

Auteurs

Carol Paton (C)

1 Royal College of Psychiatrists, Centre for Quality Improvement, London, UK.

Clive E Adams (CE)

2 Institute of Mental Health, University of Nottingham, Nottingham, UK.

Stephen Dye (S)

3 Ipswich Access and Treatment Team, Norfolk and Suffolk NHS Foundation Trust, Ipswich, UK.

Elizabeth Fagan (E)

1 Royal College of Psychiatrists, Centre for Quality Improvement, London, UK.

Chike Okocha (C)

4 Oxleas NHS Foundation Trust, Dartford, UK.

Thomas Re Barnes (TR)

1 Royal College of Psychiatrists, Centre for Quality Improvement, London, UK.
5 Centre for Psychiatry, Imperial College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH